Zusammenfassung
Die gelernte Placeboantwort im Immunsystem basiert auf der wechselseitigen Interaktion zwischen Gehirn und Immunsystem; beide Systeme tauschen über humorale und neuronale Kommunikationswege beständig Informationen aus. Basierend auf diesem Kommunikationsnetzwerk lassen sich periphere Immunfunktionen mithilfe der klassischen oder pawlowschen Konditionierung entweder supprimieren oder stimulieren. Der vorliegende Beitrag gibt einen Überblick über tierexperimentelle Befunde, die auch die potenzielle klinische Relevanz der gelernten Immunantwort dokumentieren. Immunologische Reaktionen lassen sich auch beim Menschen mithilfe der klassischen Konditionierung modifizieren. Diese experimentellen Daten und klinischen Beobachtungen eröffnen die Perspektive, die gelernte Immunantwort als supportive Maßnahme zu immunpharmakologischen Behandlungsstrategien einzusetzen, um Medikamente und damit auch unerwünschte Nebenwirkungen einzusparen, bei gleichzeitiger Maximierung der therapeutischen Effekte.
Abstract
The learned placebo response of the immune system is based on the mutual interaction between the brain and the immune system; both systems continually exchange information via humoral and neural communication pathways. This communication network enables the modification, i.e. suppression or stimulation, of peripheral immune functions by classical or Pavlov’s conditioning. The present article provides an overview of the results of recent experimental animal studies, which also document the potential clinical relevance of learned immune responses. Learned immunological responses mediated by classical conditioning have also been demonstrated in humans. The knowledge gained from experimental data and clinical observations paves the way for a potential implementation of learned immune responses as supportive measures to standard immunopharmacological treatment strategies to reduce drug dosage as well as adverse side effects while simultaneously maximizing the therapeutic effect.
Literatur
Ader R, Cohen N (1975) Behaviorally conditioned immunosuppression. Psychosom Med 37:333–340
Ader R, Mercurio MG, Walton J et al (2010) Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom Med 72:192–197
Albring A, Wendt L, Benson S et al (2014) Preserving learned immunosuppressive placebo response: perspectives for clinical application. Int J Clin Pharmacol Ther 96:247–255
Albring A, Wendt L, Benson S et al (2012) Placebo effects on the immune response in humans: the role of learning and expectation. Plos One 7:e49477
Bingel U, Colloca L, Vase LJG (2011) Mechanisms and clinical implications of the placebo effect: is there a potential for the elderly? A mini-review. Gerontology 57:354–363
Bosche K, Weissenborn K, Christians U et al (2015) Neurobehavioral consequences of small molecule-drug immunosuppression. Neuropharmacology 96:83–93
De Mattos AM, Olyaei AJ, Bennett WM (2000) Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 35:333–346
Doering BK, Rief W (2012) Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci 33:165–172
Enck P, Bingel U, Schedlowski M et al (2013) The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 12:191–204
Exton MS, Gierse C, Meier B et al (2002) Behaviorally conditioned immunosuppression in the rat is regulated via noradrenaline and beta-adrenoceptors. J Neuroimmunol 131:21–30
Exton MS, Schult M, Donath S et al (1999) Conditioned immunosuppression makes subtherapeutic cyclosporin effective via splenic innervation. Am J Physiol 276:R1710–1717
Exton MS, Schult M, Donath S et al (1998) Behavioral conditioning prolongs heart allograft survival in rats. Transplant Proc 30:2033
Goebel MU, Trebst AE, Steiner J et al (2002) Behavioral conditioning of immunosuppression is possible in humans. FASEB J 16:1869–1873
Hadamitzky M, Bosche K, Wirth T et al (2016) Memory-updating abrogates extinction of learned immunosuppression. Brain Behav Immun 52:40–48
Hadamitzky M, Luckemann L, Pacheco-Lopez G et al (2020) Pavlovian conditioning of immunological and neuroendocrine functions. Physiol Rev 100:357–405
Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715–2729
Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513
Kahl AL, Kirchhof J, Petrakova L et al (2018) Are adverse events induced by the acute administration of calcineurin inhibitor cyclosporine a behaviorally conditioned in healthy male volunteers? Clin Ther 40:1868–1877
Kirchhof J, Petrakova L, Brinkhoff A et al (2018) Learned immunosuppressive placebo responses in renal transplant patients. Proc Natl Acad Sci USA 115:4223–4227
Klosterhalfen S, Klosterhalfen W (1990) Conditioned cyclosporine effects but not conditioned taste aversion in immunized rats. Behav Neurosci 104:716–724
Klosterhalfen W, Klosterhalfen S (1983) Pavlovian conditioning of immunosuppression modifies adjuvant arthritis in rats. Behav Neurosci 97:663–666
Longo DL, Duffey PL, Kopp WC et al (1999) Conditioned immune response to interferon-gamma in humans. Clin Immunol 90:173–181
Lückemann L, Stangl H, Straub RH, Schedlowski M, Hadamitzky M (2019) Learned immunosuppressive placebo response attenuates disease progression in a rodent model of rheumatoid arthritis. Arthritis Rheumatol 72(4):588–597. https://doi.org/10.1002/art.41101
Pacheco-Lopez G, Riether C, Doenlen R et al (2009) Calcineurin inhibition in splenocytes induced by pavlovian conditioning. FASEB J 23:1161–1167
Pavlov VA, Tracey KJ (2017) Neural regulation of immunity: molecular mechanisms and clinical translation. Nat Neurosci 20:156–166
Riether C, Kavelaars A, Wirth T et al (2011) Stimulation of beta(2)-adrenergic receptors inhibits calcineurin activity in CD4(+) T cells via PKA-AKAP interaction. Brain Behav Immun 25:59–66
Schedlowski M, Enck P, Rief W et al (2015) Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev 67:697–730
Schedlowski M, Pacheco-Lopez G (2010) The learned immune response: pavlov and beyond. Brain Behav Immun 24:176–185
Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant. https://doi.org/10.1155/2012/230386
Wirth T, Ober K, Prager G et al (2011) Repeated recall of learned immunosuppression: evidence from rats and men. Brain Behav Immun 25:1444–1451
Wolf S (1959) The pharmacology of placebos
Wolf S (1950) Effects of suggestion and conditioning on the action of chemical agents in human subjects—the pharmacology of placebos. J Clin Invest 29:100–109
Förderung
Gefördert durch die Deutsche Forschungsgemeinschaft (DFG), TRR 289 Treatment Expectation, Projektnummer 422744262
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
T. Hörbelt, S. Hetze, M. Schedlowski und L. Lückemann geben an, dass kein Interessenkonflikt besteht.
Alle nationalen Richtlinien zur Haltung und zum Umgang mit Labortieren wurden eingehalten und die notwendigen Zustimmungen der zuständigen Behörden liegen vor.
Rights and permissions
About this article
Cite this article
Hörbelt, T., Hetze, S., Schedlowski, M. et al. Die gelernte Placeboantwort im Immunsystem. Nervenarzt 91, 667–674 (2020). https://doi.org/10.1007/s00115-020-00945-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-020-00945-6
Schlüsselwörter
- Assoziatives Lernen
- Klassische Konditionierung
- Gelernte Immunsuppression
- Klinische Relevanz
- Zentrales Nervensystem